FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered “undruggable.” The company’s cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP’s to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. 

Biotechnology

Pharmaceutical

FogPharma

FogPharma's headquarters in Cambridge, MA, United States

Amanda Garofalo

John Doherty

Thomas Kotarako

Marie Nguyen

Mathai Mammen

Ziyang Yu

Dave Varon

Kellon Asim Augustine Belfon

Sandra Smith

John Mcgee

Ashley Kancler

Kristen Stants

Rebecca R. Lora

Kerry Marasa Cadigan

Steve MacDonald

Tucker Lynn

Demiana Faltaos

Amber Wells

Madhumita Bogdan

Brian White

Lalith Akella

Elizabeth Adams Whicher

Anthony Quartararo

Lindsay J. Moore

Krishna Yeshwant

Barbara Weber

Edward Fitzgerald

Jeffrey Leerink

David Scadden

Keith Flaherty

Fernando Camargo

Thomas Gajewski

Corey Goodman

The Research and Development Scientists at FogPharma are instrumental in driving the discovery and optimization of cell-penetrating miniproteins (CPMPs) aimed at targeting previously "undruggable" proteins involved in serious diseases. This multidisciplinary team utilizes expertise in biology, chemistry, and computational methods to explore innovative therapeutic approaches, design novel molecules, and assess their efficacy and safety through rigorous experimental studies. Their collaborative efforts are essential for translating cutting-edge scientific research into viable treatment options.

Research and Development Scientists

The Leadership Team at FogPharma is responsible for guiding the company's strategic direction and decision-making in the pursuit of developing innovative therapies for previously untargetable diseases. Comprising key executives in discovery, clinical sciences, and human resources, the team collaborates to foster a culture of scientific excellence and drive the successful advancement of cell-penetrating miniproteins through research, clinical trials, and talent development.

Leadership Team

The Clinical and Translational Operations team at FogPharma is responsible for designing and executing clinical trials that evaluate the safety and efficacy of the company's innovative cell-penetrating miniproteins (CPMPs). This team collaborates closely with cross-functional partners to ensure seamless integration of translational research into clinical development, facilitating the transition of groundbreaking therapies from the lab to the clinic while addressing regulatory requirements and optimizing patient outcomes. Their efforts are crucial in advancing FogPharma's mission to target previously "undruggable" diseases.

Clinical and Translational Operations

The Finance and Accounting team at FogPharma is responsible for managing the company's financial operations, including budgeting, forecasting, and financial reporting. They ensure compliance with financial regulations, oversee accounts payable, and provide strategic insights to support the development and commercialization of innovative medicines. By maintaining accurate financial records and optimizing resource allocation, this team plays a crucial role in enabling the company to achieve its mission of tackling "undruggable" diseases.

Finance and Accounting

��

FogPharma

Org chart

Board & advisors

Teams

Research and Development Scientists

Leadership Team

Clinical and Translational Operations

Finance and Accounting

Offices

��������

FogPharma

Org chart

Board & advisors

Teams

Research and Development Scientists

Leadership Team

Clinical and Translational Operations

Finance and Accounting

Offices

Related companies

��